immune response enables humans (and other higher organisms) to combat pathogens
that they have never encountered before. In spite of many important
advances over the past decades, a predictive understanding of the principles
that govern the emergence of an adaptive immune response has been elusive.
The Immune Response Consortium (IRC) aims to take steps
toward the development of such predictive mechanistic principles.
A specific focus is the adaptive immune response to Listeria monocytogenes,
a class B pathogen.
The IRC is a collaboration involving scientists and engineers from MIT, Stanford University, Washington University, New York University, Memorial Sloan Ketering Cancer Center, University of California (Berkeley), and Los Alamos National Laboratory. The IRC is supported by the National Institute of Allergy and Infectious Diseases.